Condition
COVID-19 Acute Bronchitis
Total Trials
6
Recruiting
1
Active
1
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (2)
Trial Status
Completed4
Recruiting1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT05164744Recruiting
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
NCT05097677Completed
Follow-up of Covid-19 Long Term Sequelae
NCT05028244Not ApplicableCompleted
Evaluation of Serial Ultrasound Screening in ICU COVID-19 Patients
NCT04949230Completed
A Retrospective Study of COVID-19 Treatments
NCT04873349Not ApplicableCompleted
Standardized Olive Leaf Capsules; as a Co-therapy in the Treatment of COVID-19 Patients
NCT05045937Unknown
Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19
Showing all 6 trials